Multiple ascending dose study of the inhaled IL-4Ra antagonist, AZD1402/PRS-060, in mild asthmatics demonstrates robust FeNO reduction and a promising clinical profile for the treatment of asthma

Bruns BL,1 Fitzgerald MF,2 Mensing G,1 Tsung M,1 Pardali K,1 Gardiner P2 Keeling DJ,3 Axelsson LT,1 Olsson M,1 Ghobadi C,1 Walsh O,2 McLendon K,2 Farinola N,1 Hatchel L,2 Close DR2

1Pieris Pharmaceuticals, Boston, MA, USA; 2Early Respiratory, Inflammation and Autoimmunity, Biopharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden; 3Clinical Pharmacology and Safety Sciences, Biopharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden; Data Science and AI, Biopharmaceuticals R&D, AstraZeneca Gothenburg, Sweden; Nucleus Network Limited, Melbourne, Australia; Q-Pharm Pty Ltd, Herston, Australia; CMAX Clinical Research Pty Ltd, Adelaide, Australia; Linear Clinical Research Ltd, Nedlands, Australia.

Introduction

Asthma is a chronic, complex and heterogeneous respiratory disease characterized by a range of pathogenic features, including pulmonary inflammation, mucus hypersecretion, variable airway obstruction and airway remodeling.1

Methods

This was a phase 1, single-blind, randomized, dose-escalating study of multiple doses of AZD1402/PRS-060 in patients with mild asthma.

Objectives

The primary objective was to assess the safety and tolerability of cohorts 1–4, with AEs occurring in ≥ 5% of overall patients.

Results

FeNO mean ± SD at screening were 2.05 ± 1.54 and 2.23 ± 1.64 ppb, respectively, for cohorts 1 and 2. After 10 days of treatment, FeNO at day 10 was significantly lower than day 1 for all active treatments (p < 0.001).

Conclusions

The onset of FeNO reduction was rapid (after a single dose) and the maximum effect (days 4–5) versus placebo was sustained until dosing completion.

References


Author disclosures

All authors declare that they have no conflicts of interest.

Conflict of interest

All authors declare no conflicts of interest.

Supporting information

In the online version of this article, published on the journal’s website, supporting information is available.